Psychosocial effects of COVID-19 measures on (pre-)dementia patients during second lockdown

Manuscript Number: 

21-5342R2

Author(s): 
Els D. Bakker, Femke H. Bouwman, Freek Gillissen, Evelien Lemstra, Arenda Mank, Philip Scheltens, Lisa Waterink, Marissa Zwan, Mardou van Leeuwenstijn, Ingrid S. van Maurik, Marleen van de Beek, Karlijn A. van den Bosch, Jennifer R. van den Broeke, Susanne van den Buuse, Wiesje M. van der Flier

Disclosures

Els D. Bakker

  • Nothing to Disclose

Femke H. Bouwman

  • Consulting Fees:
    Biogen, advisory board for future clinical application of adecanumab Payment to institution
    Lecture Fees:
    Roche, informative lecture for Roche employees Payment to institution
    Grants
    • Agency: 
      Optina Diagnostics canada
      Dates: 
      2020-2023

Freek Gillissen

  • Nothing to Disclose

Evelien Lemstra

  • Grants
    • Agency: 
      Combinostics
      Dates: 
      2020

Arenda Mank

  • Nothing to Disclose

Philip Scheltens

  • Nothing to Disclose

Marleen van de Beek

  • Nothing to Disclose

Karlijn A. van den Bosch

  • Nothing to Disclose

Jennifer R. van den Broeke

  • Nothing to Disclose

Susanne van den Buuse

  • Nothing to Disclose

Wiesje M. van der Flier

  • Nothing to Disclose

Mardou van Leeuwenstijn

  • Nothing to Disclose

Ingrid S. van Maurik

  • Nothing to Disclose

Lisa Waterink

  • Nothing to Disclose

Marissa Zwan

  • Nothing to Disclose